Secondly, in contrast to the WHO 2017, the WHO 2022 states that somatotroph tumors are negative for PRL, raising the question how to classify bona fide somatotroph tumors with little, yet obvious intratumoral PRL expression. This evidence concerns the gene PRL and growth hormone-producing pituitary gland neoplasm.